-45.7%
RDDT vs MRNA
+945.0%
-990.8%
-64.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.0% | +13.1% | -7.1% | +5.7% |
| 7D | -24.4% | +20.6% | -45.0% | -24.7% |
| 30D | -32.3% | +27.1% | -59.4% | -32.6% |
| 3M | -36.3% | +353.4% | -389.7% | -40.2% |
| 6M | -39.7% | +446.3% | -486.0% | -46.2% |
| YTD | -55.7% | +776.2% | -831.8% | -66.0% |
| 1Y | -45.7% | +987.9% | -1,033.7% | -61.2% |
| All | -45.7% | +945.0% | -990.8% | -61.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling